Compounds > bexarotene
Page last updated: 2024-08-25

bexarotene and tacrolimus

bexarotene has been researched along with tacrolimus in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Bohmeyer, J; Gellrich, S; Kremer, A; Luger, T; Muche, M; Nashan, D; Stadler, R; Sterry, W1
Duvic, M; Huang, S; Lewis, DJ1

Reviews

1 review(s) available for bexarotene and tacrolimus

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

3 other study(ies) available for bexarotene and tacrolimus

ArticleYear
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences.
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2003, Volume: 1, Issue:10

    Topics: Adult; Aged; Aminoquinolines; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Humans; Imiquimod; Immunosuppressive Agents; Interferons; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Prednisone; PUVA Therapy; Remission Induction; Skin; Skin Neoplasms; Tacrolimus; Tetrahydronaphthalenes; Time Factors; Treatment Outcome; Vincristine

2003
Oral bexarotene for post-transplant cutaneous T-cell lymphoma.
    Dermatologic therapy, 2017, Volume: 30, Issue:5

    Topics: Administration, Oral; Anticarcinogenic Agents; Bexarotene; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Mycosis Fungoides; Skin Neoplasms; Tacrolimus; Tetrahydronaphthalenes; Treatment Outcome

2017